Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240786 | 0.85 | MEN1 (0.43) | ALDH1A1CYP1A2CYP2C19MAPTKMT2A | |
| SCHEMBL4288076 | 0.84 | SRD5A2 (0.43) | ALDH1A1CYP1A2CYP2C19MAPTKMT2A | |
| SCHEMBL4289412 | 0.84 | LMNA (0.44) | ALDH1A1MAPTKMT2AMEN1GAA | |
| SCHEMBL4288448 | 0.83 | PDGFRB (0.47) | ALDH1A1CYP1A2MAPTKMT2AMEN1 | |
| SCHEMBL532027 | 0.82 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19MAPTMAPK1 | |
| SCHEMBL2088203 | 0.81 | TUBB4A (0.49) | ALDH1A1MAPTKMT2AMEN1GAA | |
| SCHEMBL4180130 | 0.78 | MAPT (0.51) | ALDH1A1MAPTKMT2AMEN1GAA | |
| Acetic Acid Methyl Ester SCHEMBL27561416 | 0.76 | LMNA (0.46) | ALDH1A1CYP1A2CYP2C19MAPTKMT2A | |
| SCHEMBL11075503 | 0.75 | HTR1A (0.53) | ALDH1A1MAPTKMT2AMEN1GAA | |
| SCHEMBL31339552 | 0.75 | PTGS2 (0.40) | ALDH1A1CYP1A2CYP2C19MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1971596-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
| US-6407096-B1 | 1,4-BENZOTHIAZINE AND 1,4-BENZOXAZINE DERIVATIVES; HYPOTENSIVE, ANTIISCHEMIC, ANTIALLERGEN, ANTIASTHMATIC AND ANTICOAGULANT AGENTS; CARDIOVASCULAR DISORDERS | TORAY INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1028113-A1 | FUSED BENZENE HETEROCYCLE DERIVATIVES AND UTILIZATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | ALDH1A1 2708/4885CYP1A2 438/4885CYP2C19 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.